

- Eating disorders, 435
 EBNA-2 gene, 327
 E-cadherin, 12, 297
 in invasive lobular carcinoma, 1065
 in metastasis, 306-307
 Ecchymoses, 122
 Eccrine poroma, 1152
 Eclampsia, 866, 866f
 Ecthyma gangrenosum, 369b-370b
 Ectopia lentis, in Marfan syndrome, 145b
 Ectopic pregnancy, 1036
 Edema, 113-115, 114f, 115b
 clinical features of, 115
 dependent, 115
 in inflammation, 73-75, 78f
 morphology of, 115b
 pathophysiological features of, 114t
 periorbital, 115
 pitting, 115
 pulmonary, 115, 529-530, 671-672, 671t
 caused by microvascular (alveolar)
 injury, 672
 hemodynamic, 671
 noncardiogenic, 672
 subcutaneous, 115
 systemic, mechanisms of, 115f
 tissue, in right-sided heart failure, 530
 Edema factor (EF), in anthrax, 366-367
 Edwards syndrome, 162f, 163
 Effusions, 90, 113-115
 Ehlers-Danlos syndromes (EDS), 145-146,
 145t, 146b
 bleeding disorder due to, 657
 Ehrlichiosis, 384, 384f
 Eicosanoids, in inflammation, 83-86
 Eisenmenger syndrome, 533
 Elastic arteries, 484
 Elastin, extracellular matrix and, 23
 Electromechanical dissociation, 698
 Electron-dense deposits, subendothelial,
 920
 Elephantiasis, 399b, 399f
 edema due to, 114-115
 Elschnig spots, 1334
 Embolism, 127-129, 129b
 air, 128-129
 amniotic fluid, 129, 129f
 cerebral infarction due to, 1264-1265
 fat and marrow, 128, 128f
 paradoxical, 127, 533, 540
 pulmonary, 127
 systemic, 127-128
 Embolization, of thrombi, 125
 Embolus(i), 127, 127f
 cholesterol, 127
 coronary artery occlusion due to, 540
 paradoxical, 540
 saddle, 127
 small, 698
 Embryonal carcinoma, testicular, 977, 977b,
 977f
 Embryonal rhabdomyosarcoma, 1222b,
 1223f
 of bladder, 968
 of vagina, 1001
 Embryonic stem cells, 27, 27f
 Embryopathy
 diabetic, 454-455
 retinoic acid, 456
 valproic acid, 456
 Emerging infectious diseases, 400-401,
 400t
 in Global Burden of Disease, 405
 Emery-Dreifuss muscular dystrophy
 (EMD), 1244
 Emphysema, 674t, 675-678, 677b, 677t
 bullous, 678, 678f
 centriacinar (centrilobular), 675,
 675f, 676f
 clinical course of, 677
 compensatory hyperinflation, 678
 distal acinar (paraseptal), 675-676
 forms of, 678
 interstitial, 678
 irregular, 676
 obstructive overinflation, 678
 panacinar (panlobular), 675, 675f, 676f
 pathogenesis of, 676-677, 676f
 Empty sella syndrome, 1081
 Empyema, 722
 Encephalitis, mumps, 356b
 Encephalocele, 1256
 Encephalotrigeminal angiomas. *See*
 Sturge-Weber syndrome.
 Enchondromas, 1201, 1201b, 1201f,
 1202f
 End product, decreased amount of, 143
 End-stage disease, 565-567, 859
 Endemic African KS, 518
 Endemic goiter, 1091
 Endocarditis
 infective, morphology of, 125
 Libman-Sacks, 125
 nonbacterial, thrombotic, 125
 Endocervical polyps, 1002, 1002f
 Endocrine atypia, 1102b-1103b
 Endocrine disorders
 of adrenal cortex, 1122-1133
 cretinism, 1085-1086
 of pancreas, 1105-1122
 diabetes mellitus, 1105-1120
 of parathyroid glands, 1100-1105
 hyperparathyroidism as, 1101-1104
 of pineal gland, 1137
 of pituitary gland
 carcinoma as, 1080
 gonadotroph (LH-producing and
 FSH-producing) adenomas,
 1080
 nonfunctioning (silent variants,
 null-cell) adenomas, 1080
 pituitary adenomas and
 hyperpituitarism as, 1075-1080
 prolactinomas, 1078f
 thyrotroph (TSH-producing), 1080
 of thyroid
 goiter as, 1090-1092
 Graves disease, 1089-1090, 1090f
 of thyroid gland, 1082-1100
 hyperthyroidism as, 1083-1085
 hypothyroidism, 1085-1086
 thyroiditis, 1086-1089
 Endocrine neoplasm
 of adrenal cortex, 1122-1133
 pancreatic neuroendocrine, 1121-1122,
 1122f
 α -cell tumors (glucagonomas), 1122
 hyperinsulinism, 1121
 VIPoma, 1122
 Endocrine signaling, 16
 Endocrine stimulation, loss of, atrophy due
 to, 37
 Endocrine system, 1073-1139
 adrenal glands, 1122-1136
 adrenal medulla in, 1133-1136
 feedback inhibition in, 1073-1074
 multiple endocrine neoplasia syndromes,
 1136-1137
 pancreas, 1105-1122, 1117b-1119b
 parathyroid glands in, 1100-1105
 Endocrine system (*Continued*)
 pineal gland, 1137
 pituitary gland, 1074-1082
 thyroid gland, 1082-1100
 Endocrine tumors, 1136
 Endocrinopathies, paraneoplastic
 syndromes and, 330
 Endodermal sinus tumor, testicular,
 977-978
 Endogenous pyrogens, 99
 Endometrial cancer, oral contraceptives in,
 421
 Endometrial carcinoma, 1013-1014,
 1016b-1019b
 and breast carcinoma, 1053
 type I, 1014-1016, 1015f, 1016f, 1015t
 type II, 1017-1018, 1017f, 1018b
 Endometrial hyperplasia, 36, 1012-1013,
 1013b, 1014f
 Endometrial intraepithelial neoplasia,
 1013b
 Endometrial polyps, 1012
 Endometrial stroma, tumors of, 1019,
 1021b
 Endometrioid adenocarcinomas, 1016b-
 1017b, 1016f
 Endometrioid adenofibromas, 1027
 Endometrioid carcinoma, 1014, 1016b-
 1017b, 1027, 1027b
 Endometrioid tumors, ovarian, 1027,
 1027b
 Endometriosis, 1010-1012, 1011f, 1012b
 Endometriotic lesions bleed, 1012b
 Endometritis
 acute, 1010
 chronic, 1010
 Endometrium, 1007-1021
 adenosarcomas, 1019
 carcinoma of, 1013-1018
 dating of, 1007-1008
 endometriosis and adenomyosis,
 1010-1012, 1011f, 1012b
 functional endometrial disorders
 (dysfunctional uterine bleeding),
 1008-1010, 1009f, 1009t
 histology in the menstrual cycle,
 1007-1008, 1008f
 malignant mixed Müllerian tumors, 1018,
 1018b, 1019f
 malignant tumors of, 1013-1018
 stromal tumors, 1000, 1019
 Endoneurium, 1227-1228
 Endophthalmitis, 1329
 Endoplasmic reticulum (ER), 12
 Endothelial activation, 86, 486, 486f
 Endothelial and leukocyte adhesion
 molecules, 76t
 Endothelial cell(s)
 contraction of, in inflammation, 74
 vascular, in response to injury, 486
 in vascular wall response to injury,
 485-486
 Endothelial dysfunction, 486, 1117b-1119b
 Endothelial injury
 in atherosclerosis, 494
 disseminated intravascular coagulation
 due to, 663-664
 in inflammation, 74
 in septic shock, 132-133
 in thrombosis, 122-123
 in thrombotic microangiopathies,
 941-942
 Endothelial nitric oxide synthase (eNOS),
 80
 Endothelial protein C receptor, 121